A team at the University of Rochester transferred a single gene from naked mole rats into ordinary laboratory mice, and the modified animals lived about 4.4 percent longer at the median while developing fewer cancers and showing signs of healthier aging. The gene, called Has2, drives production of a sugar molecule known as high-molecular-mass hyaluronan, a substance naked mole rats produce in unusually large quantities. The result is the first demonstration that a longevity-associated gene from one mammalian species can measurably extend lifespan in another, and it raises pointed questions about how far a single molecular tweak can push the biology of aging.
Why a mole-rat gene transfer matters for aging research
Naked mole rats are biological outliers. They can live more than 30 years, roughly ten times longer than similarly sized rodents, and they almost never develop cancer. Genomic sequencing of the species confirmed this exceptional lifespan relative to body size, but pinpointing the molecular reasons took years of follow-up work. In 2013, researchers at the University of Rochester Medical Center traced the animal’s cancer resistance to a specific form of hyaluronan, a molecule found in connective tissue, skin, and joint fluid across many species. The naked mole-rat version is far larger in molecular mass than the human or mouse equivalent, and when the team knocked down HAS2 or accelerated hyaluronan degradation in mole-rat cells, those cells became vulnerable to malignant transformation.
That 2013 finding left an obvious next step: could the same gene protect a different species? The answer, published in Nature in 2023, is a qualified yes. Transgenic mice carrying the naked mole-rat Has2 gene produced elevated levels of hyaluronan across multiple tissues, showed lower rates of spontaneous cancer, and lived modestly but measurably longer. The practical significance is that a single gene swap, without caloric restriction, drug cocktails, or other interventions, shifted both cancer incidence and overall survival in a standard mammalian model.
One hypothesis worth testing in future work is whether the benefit depends on when and where the gene is active. If hyaluronan’s main contribution is dampening chronic, low-grade inflammation, the kind that accumulates with age and drives tissue deterioration, then expressing the gene under a promoter that responds to inflammatory signals rather than running constantly might produce larger gains. The published data show reduced inflammation in the transgenic mice, which is consistent with this idea, but the study used a single construct and did not compare promoter strategies head to head.
What the Rochester experiments measured
The Rochester team created transgenic mice that overexpress the naked mole-rat Has2 gene, then tracked them across their natural lifespans alongside control animals. The modified mice accumulated more hyaluronan in tissues throughout the body. Their median lifespan stretched by 4.4 percent, a figure reported in the university’s own news release distributed through the American Association for the Advancement of Science. That number is modest compared with some caloric-restriction experiments, but it came from a single genetic change rather than a lifelong dietary intervention.
Beyond raw survival, the transgenic mice scored better on several healthspan measures, meaning they stayed functionally healthier into old age. They also developed fewer spontaneous tumors, echoing the cancer resistance that first drew attention to naked mole-rat biology. The earlier 2013 study had shown that high-molecular-mass hyaluronan mediates cancer resistance in naked mole rats by triggering early contact inhibition, a cellular braking mechanism that stops growth when cells crowd together. The new mouse data suggest a version of that same protective pathway can operate across species lines.
Inflammation markers dropped in the transgenic animals as well, which matters because chronic inflammation is one of the best-documented accelerators of age-related disease in mammals, including humans. The open-access article on PubMed Central details tissue-level assays for hyaluronan quantity and molecular weight, along with pathology scoring for age-related conditions. Taken together, the data paint a picture in which a single molecule acts on multiple aging pathways at once: tumor suppression, inflammation control, and tissue maintenance.
Gaps between mole-rat biology and human medicine
A 4.4 percent median lifespan gain in mice is real, but it is not large. For context, severe caloric restriction in mice can extend median lifespan by 30 percent or more, and some combination drug regimens have achieved double-digit gains. The Rochester result shows that hyaluronan is part of the longevity equation, not that it is the whole answer. Single-gene experiments rarely capture the full complexity of aging, and the naked mole rat itself carries dozens of genetic adaptations that work in concert.
Several technical questions remain open. The published study used one transgenic construct, so the field does not yet know how expression level, tissue specificity, or timing of activation change the outcome. Would turning on Has2 only in aging animals produce a bigger or smaller effect? Would targeting the gene to specific organs, say the gut or the brain, concentrate benefits where they matter most? These are standard next steps in transgenic research, but they have not yet been systematically explored for this pathway.
There are also safety issues to consider before anyone imagines applying this work directly to humans. Hyaluronan is not an unqualified good; in some contexts and at certain molecular weights, it can promote tumor growth or fibrosis rather than prevent it. The naked mole rat appears to have evolved a finely tuned balance, combining very high-molecular-mass hyaluronan with robust mechanisms for repairing DNA damage and controlling cell division. Importing just one piece of that system into a different species might have unintended consequences over longer timescales or under different environmental stresses.
Furthermore, mice are imperfect stand-ins for people. Many interventions that extend mouse lifespan have failed to translate into clear human benefits. Metabolism, immune function, and cancer biology differ in subtle but important ways between rodents and primates. A gene that is safe and helpful in mice could behave differently in human tissues, especially over the many decades that constitute a human lifespan.
What this means for future anti-aging strategies
Even with those caveats, the Rochester work offers a roadmap for how comparative biology can inform aging research. Instead of starting from human diseases and working backward, scientists can look to naturally long-lived or disease-resistant species and identify the molecular traits that set them apart. The naked mole rat is an extreme case, but other animals, from bats to certain whales, also show unusual longevity or cancer resistance. Systematically mining those genomes for protective pathways, then testing them in tractable models like mice, could uncover a portfolio of interventions rather than a single magic bullet.
In practical terms, that portfolio might not rely on gene transfer at all. Understanding how high-molecular-mass hyaluronan protects cells could inspire small molecules that boost its production, stabilize its structure, or mimic its effects on cell signaling. Alternatively, targeted gene therapies might one day deliver Has2 or related genes to specific tissues at specific times, minimizing systemic side effects. Any such approach would require extensive preclinical testing, but the conceptual groundwork is being laid now.
The study also underscores the importance of measuring healthspan, not just lifespan. A modest increase in median survival might still be valuable if it comes with fewer cancers, less chronic inflammation, and better physical function. Conversely, an intervention that extends life but prolongs frailty would be far less appealing. By including tumor incidence and inflammatory markers alongside survival curves, the Rochester team provided a richer view of what “slower aging” looks like in practice.
For now, the naked mole-rat Has2 gene is best seen as a proof of principle. It shows that at least some aspects of extreme longevity can be transplanted across species boundaries and retain their protective effects. It also highlights how much remains unknown: why this particular hyaluronan configuration evolved, how it interacts with other mole-rat adaptations, and where its limits lie in more typical mammals. As researchers refine the tools for editing genomes and modulating gene activity, those questions will move from the realm of exotic rodent biology toward the broader goal that motivates much of aging research-the possibility of adding not just years to life, but healthy years, in a way that is safe, predictable, and grounded in the hard lessons of comparative physiology.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
